Array BioPharma Inc. (ARRY)’s COO Andrew Robbins Unloaded 17,964 Shares of the Company; Guggenheim Strategic Opportunities Fund (GOF)’s Sentiment Is 2.33

Array BioPharma Inc. (NASDAQ:ARRY) Logo

Guggenheim Strategic Opportunities Fund (GOF) investors sentiment increased to 2.33 in Q1 2018. It’s up 1.33, from 1 in 2017Q4. The ratio is positive, as 21 investment professionals started new or increased holdings, while 9 decreased and sold stock positions in Guggenheim Strategic Opportunities Fund. The investment professionals in our database now own: 2.20 million shares, up from 2.15 million shares in 2017Q4. Also, the number of investment professionals holding Guggenheim Strategic Opportunities Fund in top ten holdings was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 6 Increased: 16 New Position: 5.

Andrew Robbins, an insider of Array Biopharma Inc, currently COO lately disclosed a trade with the (SEC). As disclosed in the form, Andrew Robbins unloaded 17,964 shares of the Colorado-based Array Biopharma Inc, priced at $17.7 per share. $318,681 USD was the trade’s value. The SEC report’s date was 29-06-2018. Currently, Mr. Andrew, possess 159,467 shares, which accounts for 0.08% of the Company’s market cap.

Among 7 analysts covering Array Biopharma (NASDAQ:ARRY), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Array Biopharma has $33 highest and $17.0 lowest target. $23.14’s average target is 37.90% above currents $16.78 stock price. Array Biopharma had 13 analyst reports since January 21, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Sunday, January 21 by Stifel Nicolaus. The firm has “Outperform” rating by Leerink Swann given on Wednesday, February 7. The stock has “Overweight” rating by Cantor Fitzgerald on Monday, June 25. The rating was maintained by Piper Jaffray with “Buy” on Monday, June 25. Cowen & Co maintained the shares of ARRY in report on Sunday, January 21 with “Buy” rating. As per Wednesday, February 7, the company rating was maintained by Cowen & Co. SunTrust maintained Array BioPharma Inc. (NASDAQ:ARRY) rating on Tuesday, February 6. SunTrust has “Buy” rating and $20.0 target. The rating was maintained by Cowen & Co on Tuesday, June 5 with “Buy”. The firm earned “Buy” rating on Tuesday, February 6 by Piper Jaffray. Stifel Nicolaus maintained Array BioPharma Inc. (NASDAQ:ARRY) on Tuesday, February 6 with “Buy” rating.

Investors sentiment increased to 1.74 in 2018 Q1. Its up 0.44, from 1.3 in 2017Q4. It improved, as 16 investors sold Array BioPharma Inc. shares while 54 reduced holdings. 55 funds opened positions while 67 raised stakes. 189.71 million shares or 2.27% less from 194.11 million shares in 2017Q4 were reported. Los Angeles Capital & Equity Rech holds 116,725 shares. Credit Suisse Ag reported 228,249 shares. Parametric Port Associates Limited Co reported 207,628 shares stake. Ecor1 Limited Liability Company holds 3.05 million shares or 4.99% of its portfolio. Jane Street Grp Inc Ltd Liability Company invested in 22,581 shares. Employees Retirement Association Of Colorado holds 32,963 shares or 0% of its portfolio. Manufacturers Life The owns 0% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 147,550 shares. Moreover, Franklin Res has 0.07% invested in Array BioPharma Inc. (NASDAQ:ARRY). Td Asset Management Incorporated has invested 0% in Array BioPharma Inc. (NASDAQ:ARRY). Endurant Capital L P stated it has 0.44% in Array BioPharma Inc. (NASDAQ:ARRY). Eam Ltd Limited Liability Company reported 0.48% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY). Portfolio Solutions Limited Liability owns 215 shares. Moreover, California State Teachers Retirement Systems has 0.01% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 303,200 shares. American Research & Management has 0% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 100 shares. 13,838 are held by Quantitative Systematic Strategies Lc.

More news for Array BioPharma Inc. (NASDAQ:ARRY) were recently published by:, which released: “Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking” on June 28, 2018.‘s article titled: “Key events next week – healthcare” and published on June 21, 2018 is yet another important article.

Since January 16, 2018, it had 0 insider purchases, and 11 sales for $6.95 million activity. VAN LUNSEN GIL J also sold $326,585 worth of Array BioPharma Inc. (NASDAQ:ARRY) shares. Sandor Victor had sold 156,016 shares worth $2.76 million on Friday, March 9. $102,975 worth of Array BioPharma Inc. (NASDAQ:ARRY) shares were sold by Haddock Jason.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company has market cap of $3.53 billion. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. It currently has negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

The stock decreased 0.71% or $0.12 during the last trading session, reaching $16.78. About 3.16 million shares traded or 14.74% up from the average. Array BioPharma Inc. (NASDAQ:ARRY) has risen 92.14% since July 1, 2017 and is uptrending. It has outperformed by 79.57% the S&P500. Some Historical ARRY News: 22/03/2018 – ARRAY: TRIAL SHOWED MEDIAN PROGRESSION-FREE SURVIVAL 14.9 MOS; 16/04/2018 – IN CHECKMATE -141, OPDIVO (NIVOLUMAB) DEMONSTRATED SUSTAINED OVERALL SURVIVAL (OS) ADVANTAGE OVER STANDARD OF CARE IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND; 06/04/2018 – Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination With KEYTRUDA(R) (pembrolizumab) in Patients With Unresectable or Metastatic Melanoma; 26/03/2018 – Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Four-Week Dosing Schedule for Advanced; 13/03/2018 – FDA GRANTS PRIORITY REVIEW TO MERCK’S SBLA (SBLA) FOR KEYTRUDA®; 06/03/2018 – Bristol-Myers: Opdivo Also Now Approved for Shorter 30-Minute Infusions; 13/03/2018 – FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Advanced Cervical Cancer; 17/05/2018 – Eisai Announces Data at ASCO 2018 Annual Meeting Showcasing LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy Under Strategic Oncology Collaboration with Merck; 01/05/2018 – Merck Boosts Outlook as Keytruda Sales Surpass Diabetes Drugs; 09/05/2018 – ARRAY BIOPHARMA 3Q LOSS/SHR 11C, EST. LOSS/SHR 23C

Analysts await Array BioPharma Inc. (NASDAQ:ARRY) to report earnings on August, 8. They expect $-0.25 earnings per share, down 47.06% or $0.08 from last year’s $-0.17 per share. After $-0.11 actual earnings per share reported by Array BioPharma Inc. for the previous quarter, Wall Street now forecasts 127.27% negative EPS growth.

The stock increased 0.46% or $0.1 during the last trading session, reaching $21.95. About 157,641 shares traded or 9.18% up from the average. Guggenheim Strategic Opportunities Fund (GOF) has risen 1.24% since July 1, 2017 and is uptrending. It has underperformed by 11.33% the S&P500.

Cordasco Financial Network holds 0.08% of its portfolio in Guggenheim Strategic Opportunities Fund for 3,487 shares. Sigma Planning Corp owns 38,369 shares or 0.06% of their US portfolio. Moreover, Usca Ria Llc has 0.03% invested in the company for 12,852 shares. The Colorado-based Advisors Asset Management Inc. has invested 0.02% in the stock. Bb&T Securities Llc, a Virginia-based fund reported 24,572 shares.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Chart